1 |
Theodosis-Nobelos P, Rekka EA. The Multiple Sclerosis Modulatory Potential of Natural Multi-Targeting Antioxidants. Molecules 2022;27. [PMID: 36500494 DOI: 10.3390/molecules27238402] [Reference Citation Analysis]
|
2 |
Assogna M, Di Lorenzo F, Martorana A, Koch G. Synaptic Effects of Palmitoylethanolamide in Neurodegenerative Disorders. Biomolecules 2022;12:1161. [PMID: 36009055 DOI: 10.3390/biom12081161] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
3 |
Cristiano C, Avagliano C, Cuozzo M, Liguori FM, Calignano A, Russo R. The Beneficial Effects of Ultramicronized Palmitoylethanolamide in the Management of Neuropathic Pain and Associated Mood Disorders Induced by Paclitaxel in Mice. Biomolecules 2022;12:1155. [PMID: 36009049 DOI: 10.3390/biom12081155] [Reference Citation Analysis]
|
4 |
De Luca P, Camaioni A, Marra P, Salzano G, Carriere G, Ricciardi L, Pucci R, Montemurro N, Brenner MJ, Di Stadio A. Effect of Ultra-Micronized Palmitoylethanolamide and Luteolin on Olfaction and Memory in Patients with Long COVID: Results of a Longitudinal Study. Cells 2022;11:2552. [DOI: 10.3390/cells11162552] [Reference Citation Analysis]
|
5 |
Palese F, Pontis S, Realini N, Torrens A, Ahmed F, Assogna F, Pellicano C, Bossù P, Spalletta G, Green K, Piomelli D. Targeting NAAA counters dopamine neuron loss and symptom progression in mouse models of parkinsonism. Pharmacol Res 2022;182:106338. [PMID: 35781057 DOI: 10.1016/j.phrs.2022.106338] [Reference Citation Analysis]
|
6 |
Colizzi M, Bortoletto R, Colli C, Bonomo E, Pagliaro D, Maso E, Di Gennaro G, Balestrieri M. Therapeutic effect of palmitoylethanolamide in cognitive decline: A systematic review and preliminary meta-analysis of preclinical and clinical evidence. Front Psychiatry 2022;13:1038122. [PMID: 36387000 DOI: 10.3389/fpsyt.2022.1038122] [Reference Citation Analysis]
|